{"data":{"type":"company_profile_ai","id":73723,"entity_id":"wefunder:company:73723","attributes":{"canonical_url":"https://wefunder.com/squarexllc","retrieval_urls":{"canonical":"https://wefunder.com/squarexllc","json":"https://wefunder.com/squarexllc.json","markdown":"https://wefunder.com/squarexllc.md","ai_json":"https://wefunder.com/squarexllc.ai.json","ai_text":"https://wefunder.com/squarexllc.ai.txt","changelog_json":"https://wefunder.com/squarexllc.changelog.json","schema":"https://wefunder.com/.well-known/ai-profile-schema.json"},"updated_at":"2026-06-27T05:04:03Z","generated_at":"2026-06-27T21:16:21Z","profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"company":{"id":73723,"entity_id":"wefunder:company:73723","slug":"squarexllc","name":"Squarex, LLC","tagline":"Preventing oral herpes with a topical application to the arm","elevator_pitch":"We are developing a drug that prevents cold sores or oral herpes outbreaks in people with frequent outbreaks. The drug has completed Phase 2 clinical trials and has worked great. It significantly reduces the number and severity of cold sores, with 1 topical dose to the arm (not the face or lip) every 3 months. It acts by boosting immune function.","location":"Saint Paul, MN","website":"https://Squarex-pharma.com","total_amount_raised":235067,"total_investors":164,"is_funded":true,"is_active":true},"key_claims":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 235067","citation":"https://wefunder.com/squarexllc#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-27T05:04:03Z","as_of":"2026-06-27T21:16:21Z","confidence":"high"},"observed_at":"2026-06-27T05:04:03Z","expires_at":"2026-06-28T05:04:03Z"},{"claim_id":"claim-total-investors","text":"Total investors: 164","citation":"https://wefunder.com/squarexllc#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-27T05:04:03Z","as_of":"2026-06-27T21:16:21Z","confidence":"high"},"observed_at":"2026-06-27T05:04:03Z","expires_at":"2026-06-28T05:04:03Z"}],"verified_facts":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 235067","citation":"https://wefunder.com/squarexllc#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-27T05:04:03Z","as_of":"2026-06-27T21:16:21Z","confidence":"high"},"observed_at":"2026-06-27T05:04:03Z","expires_at":"2026-06-28T05:04:03Z"},{"claim_id":"claim-total-investors","text":"Total investors: 164","citation":"https://wefunder.com/squarexllc#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-27T05:04:03Z","as_of":"2026-06-27T21:16:21Z","confidence":"high"},"observed_at":"2026-06-27T05:04:03Z","expires_at":"2026-06-28T05:04:03Z"}],"company_claims":{"tagline":"Preventing oral herpes with a topical application to the arm","elevator_pitch":"We are developing a drug that prevents cold sores or oral herpes outbreaks in people with frequent outbreaks. The drug has completed Phase 2 clinical trials and has worked great. It significantly reduces the number and severity of cold sores, with 1 topical dose to the arm (not the face or lip) every 3 months. It acts by boosting immune function.","story":"\u0026gt;50% of persons suffer from HSV-1 infection15% of adults have 1 or more cold sore outbreaks annually2.1% of adults have 6+ outbreaks annuallyIn today’s oral herpes market, over 15% of the world population suffers from annual cold sore outbreaks with no means of prevention. Available treatments must be administered within hours of the first sign of a tingle, well before an open sore or redness develops, which is not feasible in many or most cases, and even then they only act to shorten the length of outbreaks once they occur, and only shorten the length by about 20% at most.SolutionSQUAREX: Prevention of Oral HerpesSquarex, developers of SQX770, a first-in-class immunomodulator that prevents Oral Herpes outbreaks for over 4 months with just a single topical application to the arm, offers relief to those suffering from cold sores.ProductSQUAREX Technology\u0026nbsp;SQX770 is a topical immuno-sensitizer that prevents HSV-1 outbreaks though it’s active ingredient, Squaric Acid Dibutyl Ester (SADBE), which has been proven effective in preventing cold sores in two randomized double-blind placebo controlled clinical trials.SQX770 is easy to administer during or between outbreaks, requiring only a single dose to the arm to PREVENT outbreaks for 4 months or even longer. This means that annual prevention is sustained through just 4 quarterly applications.PatentsSquarex owns issued U.S. and foreign patents that provide market exclusivity for topical SQX770 in the US, as well as Japan, Canada, and Europe until at least 2036.\u0026nbsp; Additional patent applications not yet issued are pending in Europe, China, Canada, Japan, India, \u0026amp; Australia.The following patents are issued in the U.S.U.S. Patent No. 10,245,314U.S. Patent No. 10,940,197U.S. Patent No. 9,205,065U.S. Patent No. 10,744,084TractionSQX770 - Effective in All 3 Clinical Trials PHASE 144 persons, all reported 6+ outbreaks in prior year, treated on day 1 with Squaric Acid Dibutyl Ester (SADBE) or placebo.TRIPLED time to next cold sore outbreak versus placebo.No serious adverse events (mild reversible redness at sensitization site)PHASE 2 Mechanism of ActionPart 1. 36 persons, all anti-HSV1+ withGood immune control (0-2 outbreaks per year)Bad immune control (6+ outbreaks per year).Blood tests of immune function on day 1Result: Those with fewer outbreaks, better immune control had:Higher T-cell, type 1 immune responseLower antibody, type 2 immune responsePart 2. Effect of SQX770Patients with 6+ outbreaks per year were dosed once with SADBE on day 1. Immune tests repeated 8 weeks later.Result: SQX770 Improves the Immune Systems Response to HSV-1 Eight Weeks After Just ONE DoseIncreased immune cell proliferation to HSV-1 virusImproved immune gene expression against HSV-1 virus Restored immune levels even beyond that seen in persons with infrequent or zero outbreaksShifted immune response from type 2, antibody, response, to more effective type 1, T cell, response.PHASE 2139 patients with 4+ outbreaks per year, treated with Squaric Acid Dibutyl Ester (SADBE) replicated earlier Phase 1 outcome:Reduced frequency of cold sore outbreaksReduced severity of cold sore outbreaksMaximal effectiveness after initial immune training period, similar to a vaccineSafe \u0026amp; effective up to 4 monthsMarketA $1.29B Market by 2028 According to the report published by Data Bridge Market Research, in 2021 the global market for treating oral herpes is valued at $274M USD, and it is estimated that by the end of 2028 it will reach a valuation of $1.29B USD. The increase in market valuation will be driven by the increment of the number of new cases over time.SQUAREX plans to progress forward to FDA Approval through two simultaneous 12-month Phase 3 trials, with 1,800 patients, in the process of bringing SQX770 to market as the ONLY drug we believe to prevent HSV-1 outbreaks. Sales Revenue \u0026amp; Market PlansSales Revenue ForecastThe table below represents valuation scenarios based on multiples of enterprise value to revenues. We believe these estimates represent fairly both the growth potential and inherent risks in the Squarex business model. These projections are forward-looking and cannot be guaranteed.Disclaimer: These projections cannot be guaranteedCompany expects to complete a US FDA Phase 3 clinical Trial and to begin commercializing its product by 2025. Based on standard industry practices, it is important for investors to focus on year 2025 revenues and beyond. For example, should we meet our revenue expectations in 2026, transacting at a conservative revenue multiple of only 2.25X would represent a 400% gain to existing shareholders. These projections cannot be guaranteed.Market PlansSQX770 planned market entry opportunities leverage sales force partnerships to access physicians \u0026amp; D2C, including television \u0026amp; online marketing – comparable to other pharmaceuticals. Additionally, Squarex may partner with major pharmaceutical entities for market penetration and growth. Potential Exit Opportunities\u0026nbsp;These potential exit opportunities are included to illustrate possible scenarios; none of these possibilities can be guaranteed.M \u0026amp; ABig Pharma continually seeks out new products through the use of Brokers, consultants, and industry insiders. Squarex would be an attractive acquisition or licensing opportunity for large pharmaceutical companies, both pre-and post-approval and revenue of the Squarex lead drug.PartneringSquarex may partner with an established pharmaceutical company, particularly one with a sales and marketing team that fits the Squarex product market, to market the Squarex product more efficiently.\u0026nbsp;Initial Public Offering (IPO)Public markets are open and looking for new promising companies, providing greater liquidity and valuation. Squarex will consider an IPO within the next two to three years, which would give the current investors liquidity. CompetitionThe ONLY Way to Prevent Oral HerpesAvailable remedies for Oral Herpes from Abreva \u0026amp; Valtrex are for “treatment only,” must be taken within hours of feeling the first signs of a tingle, well before an open sore or redness develops, and only act to shorten the length of outbreaks once they occur. This includes drugs currently in clinical trials, other than SQX770. Because no other drug currently available, or in clinical trials, prevents cold sores, SQX770 is positioned to disrupt \u0026amp; dominate the HSV medication market. VisionLong Term Solution for Millions of People Suffering from Oral HerpesWith your investment, SQUAREX will make a sustainable impact on the millions of people suffering from Oral Herpes through our further development and market launch of SQX770. And we won’t stop there, as our technology has the further potential to similarly address Genital Herpes and other viruses.Timeline \u0026amp; Use of Funds (raising $1.07M on Wefunder)$5M Capital Raise, 18 MONTHS: Phase 2 Bridging StudyDrug manufacture and stability testing.Further animal safety testing.$20-40M Capital Raise, 13 - 36 MONTHS: Phase 3 Clinical TrialsNew Drug ApplicationINVESTING IN PREVENTION OF ORAL HERPESEARLY STAGE STARTUP OPPORTUNITY. When you invest in Squarex you are buying stock in an Early Stage startup — like investing in Gilead Sciences when it was just the founders, and where the company now garners annual revenues of approximately $24B. Such successful companies are often measured in tens or hundreds of billions of dollars— you are buying into Squarex at an early stage valuation. There are always risks in investing (see below) so investing in strong teams, with strong products, and successful backgrounds such as Squarex embodies helps limit risk while seeking high returns.OPEN TO ALL INVESTORS. Prior to the JOBS ACT, investing in early-stage startups was not an option for non-accredited investors, and now everyone has the opportunity to participate in the startup economy. With approximately $6 million invested in its lead drug SQX770 and in enterprise development, and as creator of the only drug shown to prevent cold sore outbreaks, and the only drug that reduces both the frequency and severity of cold sore outbreaks.FOUNDERSHugh McTavishFounder \u0026amp; CEO, Ph.D. biochemist and patent attorney, and inventor of the company's drug. Hugh has additionally founded a company with a targeted cancer drug as well as a nonprofit. “I invented this treatment to cure my own frequent cold sores. At the time I was having almost constant cold sores, and I had had frequent colds sores my whole life. After trying this on myself, I have fewer than 1 cold sore episode per year now. We want to help other people with this painful, annoying, and embarrassing condition.”Thomas D. HornThomas D. Horn, M.D., is the co-founder of the company, co-inventor of the company’s technology, and an advisor to Squarex. He is a dermatologist, is on the dermatopathology Faculty at Harvard Medical School, and is former Executive Director of the American Board of Dermatology.Management TeamKathleen Littrell Kathleen Littrell, M.S., is Squarex’s Vice President for Business Development and Clinical Development. She is a scientist and manages the Company's clinical trials. She has over 10 years of working experience in all aspects of clinical trials. Arkadiusz DudekArkadiusz Dudek, M.D., Chief Medical Officer and Board Member of Squarex, is a practicing physician at Regions Hospital, Saint Paul, MN, and a professor at the University of Minnesota Medical School. He has previously been on the faculty at the University of Illinois Chicago medical school. He has extensive experience in clinical trial design \u0026amp; is also on the Board of IGF Oncology and other small pharmaceutical companies.Gary Hildebrand Gary Hildebrand, J.D., Board Member, is a licensed attorney, army veteran, and past president of two industrial technology companies, and consultant to several companies.Joe Cunningham Joe Cunningham, CFO, has a multi-faceted background and an institutional toolbox to help realize Squarex’s ambitions. As an economist and former investment banker, he has raised over $5 billion. He has run public and private companies globally, led complex negotiations, handled complicated deal structures, managed investors relations, structured and executed numerous deals, run legal and compliance, developed and implemented strategy; and, as a CFO, he has run the day-to-day functions of diverse and often global finance departments. Joe’s experience in pharmaceuticals includes Healthcare Management Asia, Systems for Health Management (a clinical trail data management company), AXM Pharma and Gamma Pharmaceuticals. Previously, as an investment banker he worked for BNP Paribas in Singapore and ANZ Investment Bank in Singapore and London and as an economist for Polyconomics in New York. Joe Graduated from Northeastern University (Boston) with a BS in Economics and has an MBA from the Thunderbird School of Global Management.","quick_facts":["Successfully completed Phase 2 clinical trials with clear path to commercialization","A single topical dose to the arm prevents outbreaks for over 4 months","Clinical trials conducted at Harvard and Stanford","Raised $5.75M in initial seed round","Global Oral Herpes Market projected $1.29B by 2028","Cofounded by former Executive Director of the American Board of Dermatology"]},"computed_metrics":{"total_amount_raised":235067,"total_investors":164,"team_size":6,"featured_investor_count":1,"faq_count":5,"recent_post_count":9},"quick_facts":[{"claim_id":"claim-fact-1","value":"Successfully completed Phase 2 clinical trials with clear path to commercialization","citation":"https://wefunder.com/squarexllc#claim-fact-1","observed_at":"2026-06-27T05:04:03Z","expires_at":"2026-07-04T05:04:03Z"},{"claim_id":"claim-fact-2","value":"A single topical dose to the arm prevents outbreaks for over 4 months","citation":"https://wefunder.com/squarexllc#claim-fact-2","observed_at":"2026-06-27T05:04:03Z","expires_at":"2026-07-04T05:04:03Z"},{"claim_id":"claim-fact-3","value":"Clinical trials conducted at Harvard and Stanford","citation":"https://wefunder.com/squarexllc#claim-fact-3","observed_at":"2026-06-27T05:04:03Z","expires_at":"2026-07-04T05:04:03Z"},{"claim_id":"claim-fact-4","value":"Raised $5.75M in initial seed round","citation":"https://wefunder.com/squarexllc#claim-fact-4","observed_at":"2026-06-27T05:04:03Z","expires_at":"2026-07-04T05:04:03Z"},{"claim_id":"claim-fact-5","value":"Global Oral Herpes Market projected $1.29B by 2028","citation":"https://wefunder.com/squarexllc#claim-fact-5","observed_at":"2026-06-27T05:04:03Z","expires_at":"2026-07-04T05:04:03Z"},{"claim_id":"claim-fact-6","value":"Cofounded by former Executive Director of the American Board of Dermatology","citation":"https://wefunder.com/squarexllc#claim-fact-6","observed_at":"2026-06-27T05:04:03Z","expires_at":"2026-07-04T05:04:03Z"}],"latest_fundraise":{"id":39656,"entity_id":"wefunder:fundraise:39656","state":"successful","offering_type":"4(a)(6)","structure":"safe","testing_the_waters":false,"can_invest_now":false,"funding_started_at":"2021-09-13T22:24:03Z","funding_closed_at":"2022-03-01T05:03:35Z"},"investor_memos":[],"team":[{"id":1272944,"entity_id":"wefunder:company_role:1272944","name":"Hugh McTavish","title":"Founder and CEO","role":"founder","profile_url":"https://wefunder.com/hughmctavish2"},{"id":1772580,"entity_id":"wefunder:company_role:1772580","name":"Thomas D. Horn","title":" Co-Founder","role":"founder"},{"id":1772582,"entity_id":"wefunder:company_role:1772582","name":"Kathleen Littrell","title":"Vice President for Business Development","role":"employee"},{"id":1772584,"entity_id":"wefunder:company_role:1772584","name":"Arkadiusz Dudek","title":"Chief Medical Officer \u0026 Board Member","role":"employee","profile_url":"https://wefunder.com/arkadiuszdudek"},{"id":1772585,"entity_id":"wefunder:company_role:1772585","name":"Gary Hildebrand","title":"Board Member","role":"employee"},{"id":1772586,"entity_id":"wefunder:company_role:1772586","name":"Joseph Cunningham","title":"CFO","role":"employee","profile_url":"https://wefunder.com/josephcunningham"}],"featured_investors":[{"id":5596,"entity_id":"wefunder:company_investor_profile:5596","name":"Lucas Langworthy","profile_url":"https://wefunder.com/lucaslangworthy"}],"relationships":[{"source_entity_id":"wefunder:company:73723","relation":"has_team_member","target_entity_id":"wefunder:user:1243516","target_url":"https://wefunder.com/hughmctavish2"},{"source_entity_id":"wefunder:company:73723","relation":"has_team_member","target_entity_id":"wefunder:company_role:1772580"},{"source_entity_id":"wefunder:company:73723","relation":"has_team_member","target_entity_id":"wefunder:company_role:1772582"},{"source_entity_id":"wefunder:company:73723","relation":"has_team_member","target_entity_id":"wefunder:user:1233510","target_url":"https://wefunder.com/arkadiuszdudek"},{"source_entity_id":"wefunder:company:73723","relation":"has_team_member","target_entity_id":"wefunder:company_role:1772585"},{"source_entity_id":"wefunder:company:73723","relation":"has_team_member","target_entity_id":"wefunder:user:1456371","target_url":"https://wefunder.com/josephcunningham"},{"source_entity_id":"wefunder:company:73723","relation":"has_featured_investor","target_entity_id":"wefunder:user:1966919","target_url":"https://wefunder.com/lucaslangworthy"},{"source_entity_id":"wefunder:company:73723","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:153007","target_url":"https://wefunder.com/feed/153007"},{"source_entity_id":"wefunder:company:73723","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:152728","target_url":"https://wefunder.com/feed/152728"},{"source_entity_id":"wefunder:company:73723","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:151806","target_url":"https://wefunder.com/feed/151806"},{"source_entity_id":"wefunder:company:73723","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:150584","target_url":"https://wefunder.com/feed/150584"},{"source_entity_id":"wefunder:company:73723","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:149001","target_url":"https://wefunder.com/feed/149001"},{"source_entity_id":"wefunder:company:73723","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:148912","target_url":"https://wefunder.com/feed/148912"},{"source_entity_id":"wefunder:company:73723","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:148605","target_url":"https://wefunder.com/feed/148605"},{"source_entity_id":"wefunder:company:73723","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:147506","target_url":"https://wefunder.com/feed/147506"},{"source_entity_id":"wefunder:company:73723","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:146283","target_url":"https://wefunder.com/feed/146283"},{"source_entity_id":"wefunder:company:73723","relation":"has_latest_fundraise","target_entity_id":"wefunder:fundraise:39656"}],"faq":[{"question":"Is the future equity common or preferred, and are you all planning on remaining an LLC for tax purposes prior to any IPO?","answer":"The future equity is preferred. It would be an LLC currently and we plan on remaining an LLC until we go public, for tax purposes as you say. When we go public we would become a C corporation and your equity would be preferred stock, and I would like to take the company public."},{"question":"Hello, how many people participated in the clinical trials to date?","answer":"43 in Phase 1, 29 of whom got real drug and the rest placebo. 32 in a mechanism of action clinical trial got real drug. 143 in Phase 2, of whom 2/3 got real drug. In total about 150 people have been dosed with SQX770."},{"question":"Could you explain your valuation?","answer":"Hi Nelson, it's Joe Cunningham, Squarex's CFO please note the following DCF calculations. Please know we look at the valuation from a number of different perspectives. We use various methods including a discounted cash flow and comparative marginal analysis. Ultimately it's a function of demographics. 15% of the adult population has 1 or more cold sore outbreaks each year, and 2.1% has 6 or more per year. Approximately 3-4%, therefore, have 4 or more outbreaks per year. The condition is about..."},{"question":"Hello. Is the finished product envisioned to be applied by a physician or would it be in-home use by the patient themselves?","answer":"It will be applied by the patient at home. It would be sold like an ordinary prescription drug, picked up at the pharmacy, and applied at home. That is more convenient for patients and better for our business than if it were sold and applied at physicians' offices."},{"question":"When will this product be available for public use?","answer":"That depends on fundraising. If we are successful in this raise and raising the investment money we need to complete the Phase 3 trials, it could be available in as soon as 2 years."}],"recent_posts":[{"id":153007,"entity_id":"wefunder:feed_item:153007","title":"Squarex Wefunder Campaign is Closing1 Last Chance to Invest by Feb. 28! Team had success before with another pharma company.","preview":"Squarex's investment campaign on Wefunder is closing on February 28!\u0026nbsp;This is your last chance to invest before Squarex is a public company.\u0026nbsp;\u0026nbsp;My team has urged me to toot our horn on our previous success.\u0026nbsp;I previously invented a family of targeted cancer drugs and started a company around that called IGF Oncology.\u0026nbsp;IGF's lead drug has worked well in clinical trials in a bone marrow cancer called myelodysplastic syndrome (MDS).\u0026nbsp;And we recently licensed the rights to...","published_at":"2022-02-24T20:14:24Z","canonical_url":"https://wefunder.com/feed/153007"},{"id":152728,"entity_id":"wefunder:feed_item:152728","title":"Squarex Wefunder Campaign Closing on February 28","preview":"Squarex\u0026nbsp;has appointed an investment bank to pursue strategic\u0026nbsp;options for the company.\u0026nbsp;Regulation Fair Disclosure\u0026nbsp;(Reg FD) prohibits us from expounding further on the nature of that relationship.\u0026nbsp;\u0026nbsp;As such, we are closing the Wefunder raise.\u0026nbsp;Please complete your investments in Squarex by end of the day on Monday, February 28.\u0026nbsp;Thank you for supporting Squarex.\u0026nbsp;We look forward\u0026nbsp;to keeping you up to date regarding our progress as we move through the...","published_at":"2022-02-15T02:06:24Z","canonical_url":"https://wefunder.com/feed/152728"},{"id":151806,"entity_id":"wefunder:feed_item:151806","title":"Investment Bank Update","preview":"Squarex\u0026nbsp;is currently interviewing investment banks and is likely to announce our banking partner as early as next week.\u0026nbsp;We will then move on to finalizing Reverse Merger plans.This is in relation to our prior update:\u0026nbsp;\"Squarex has executed a term sheet that would result in the company\u0026nbsp;going public.\u0026nbsp;The term sheet is with a health-care-focused venture capital firm for an investment of $12.5 million concurrent with a merger into a NASDAQ or NYSE publicly traded company t...","published_at":"2022-01-06T20:11:45Z","canonical_url":"https://wefunder.com/feed/151806"},{"id":150584,"entity_id":"wefunder:feed_item:150584","title":"Squarex Pharma has signed a term sheet to go public and receive $12 to 75 million investment.","preview":"I am very pleased to inform you that Squarex has executed a term sheet that would result in the company\u0026nbsp;going public.\u0026nbsp;The term sheet is with a health-care-focused venture capital firm for an investment of $12.5 million concurrent with a merger into a NASDAQ or NYSE publicly traded company that is yet to be identified, with follow-on investment by the same firm of up to 62.5\u0026nbsp;million.\u0026nbsp;Squarex is in the process of identifying suitable candidate companies to merge into by reve...","published_at":"2021-11-22T22:38:24Z","canonical_url":"https://wefunder.com/feed/150584"},{"id":149001,"entity_id":"wefunder:feed_item:149001","title":"Webinar: Squarex Pharma--the only drug that prevents cold sores. Tuesday 9/28 at 7 pm Central. Forward and invite your friends!","preview":"Hi,We are holding a Zoom webinar this Tuesday night at 7 pm Central (8 pm Eastern, 5 pm Pacific).\u0026nbsp;Hugh McTavish, the CEO, and Joe Cunningham, the CFO will give a short presentation and be available to answer your questions.\u0026nbsp;PLEASE INVITE YOUR FRIENDS!!\u0026nbsp;I also remind you that we have a finders program and if you introduce someone who invests $1,000 to $9,999, you get $100 worth of equity on the same terms as them, and if they invest $10,000 or greater, you get $1,000 of equity.\u0026...","published_at":"2021-09-25T20:08:04Z","canonical_url":"https://wefunder.com/feed/149001"},{"id":148912,"entity_id":"wefunder:feed_item:148912","title":"Money Nation-Squarex-CEO \u0026amp; Founder Hugh McTavish-Ed Gardner-Podcast Interview","preview":"\"Join us here on Money Nation in watching our host, Ed Gardner, interview guest Hugh McTavish, Founder and Chief Scientist of Squarex, talks about Squarex and the company's related investment opportunity. Squarex is developing the only drug shown to prevent oral herpes with future applications possible for genital herpes and more. Squarex is a clinical stage pharmaceutical company developing a topical formulation of the immunomodulator squaric acid dibutyl ester for prevention of recurrent co...","published_at":"2021-09-22T22:25:30Z","canonical_url":"https://wefunder.com/feed/148912"},{"id":148605,"entity_id":"wefunder:feed_item:148605","title":"Wefunder has filed the Form C for Squarex! We can now officially accept investments!","preview":"Wefunder has filed the Form C for Squarex with the U.S. Securities and Exchange Commission.\u0026nbsp; This step is necessary for us to accept actual investments, instead of just \"testing the waters\" under Regulation Crowdfunding. So for those who have pledged investment, please take the steps on Wefunder to complete your investment on Wefunder.\u0026nbsp; Your investment will go into escrow for now.\u0026nbsp;\u0026nbsp;","published_at":"2021-09-14T15:29:41Z","canonical_url":"https://wefunder.com/feed/148605"},{"id":147506,"entity_id":"wefunder:feed_item:147506","title":"Squarex Passes the $70k Mark. Discussing Strategic Partnerships.","preview":"Passing the $70k MarkThank you all for helping Squarex LLC surpass the $70k mark.\u0026nbsp;\"I'm enthused by the investment momentum achieved through the Wefunder network.\u0026nbsp;Together, we can help prevent cold sore outbreaks.\"\u0026nbsp;- Founder, CEO, \u0026 Chief Scientist Hugh McTavish\u0026nbsp;Strategic PartnershipsSquarex has recently entered into discussions with Strategic Partners, including potential reach to world-wide markets.\u0026nbsp;More updates to come as we explore these opportunities.","published_at":"2021-08-09T21:05:16Z","canonical_url":"https://wefunder.com/feed/147506"},{"id":146283,"entity_id":"wefunder:feed_item:146283","title":"Together, WE can Prevent Herpes Outbreaks!","preview":"At Squarex, we've been reaching out to active communities found on Reddit, Facebook, \u0026 more, where so many are affected by HPV-1 \u0026 HPV-2, and are actively seeking Prevention.\u0026nbsp; Squarex welcomes \u0026 appreciates YOUR support here on Wefunder and in helping us reach out to these communities, providing awareness of the Squarex opportunity.\u0026nbsp; If you know any groups we should be connecting with, please help us reach out to them.\u0026nbsp; Together, WE can prevent Herpes Outbreaks.\u0026nbsp;\u0026nbsp;","published_at":"2021-06-28T22:18:42Z","canonical_url":"https://wefunder.com/feed/146283"}],"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-27T21:16:21Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-27T05:04:03Z","as_of":"2026-06-27T21:16:21Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-27T05:04:03Z","as_of":"2026-06-27T21:16:21Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2025-02-06T01:17:55Z","as_of":"2026-06-27T21:16:21Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2025-02-06T01:17:55Z","as_of":"2026-06-27T21:16:21Z","confidence":"medium"}}}}}}